Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2022; 12(6):2773-2800. doi:10.7150/thno.70001 This issue Cite

Review

Theranostic nanoparticles for the management of thrombosis

Peije Russell1, Christoph Eugen Hagemeyer2, Lars Esser1,3✉, Nicolas Hans Voelcker1,3,4,5✉

1. Drug Delivery, Disposition & Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia.
2. NanoBiotechnology Group, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, 3004, Australia.
3. Commonwealth Scientific and Industrial Research Organisation (CSIRO), Manufacturing, Clayton, Victoria, 3168, Australia.
4. Melbourne Centre for Nanofabrication, Victorian Node of Australian National Fabrication Facility, Clayton, Victoria, 3168, Australia.
5. Department of Materials Science and Engineering, Monash University, Clayton, Victoria, 3800, Australia.

✉ Corresponding authors: E-mail: lars.esserau, nicolas.voelckeredu.

Citation:
Russell P, Hagemeyer CE, Esser L, Voelcker NH. Theranostic nanoparticles for the management of thrombosis. Theranostics 2022; 12(6):2773-2800. doi:10.7150/thno.70001. https://www.thno.org/v12p2773.htm
Other styles

File import instruction

Abstract

Graphic abstract

Acute thrombosis and thromboembolisms are one of the leading causes of mortality and morbidity in both developed and developing countries, placing a huge burden on health and economic systems. Early diagnosis is critical but currently limited in accuracy and hampered by a narrow time frame, where the short therapeutic window also severely restricts treatment options. Additionally, clinically used antithrombotics and thrombolytics suffer from severe side effects and are limited in efficacy by a short half-life and susceptibility to degradation. The use of systems containing both diagnostic and therapeutic moieties, known as theranostics, can potentially improve patient outcomes by increasing the precision and efficacy of diagnosis and treatment, enabling personalised and precision medicine. Leveraging nanomedicine may further improve treatment by improving the system's pharmacokinetic properties including controlled drug delivery. This review provides an overview of the development of such theranostic nanoparticle systems, with a focus on approaches that may be utilised to usher this field towards clinical use.

Keywords: Thrombosis, Theranostics, Nanomedicine, Diagnostic imaging, Thrombolytic therapy

Citation styles

APA
Russell, P., Hagemeyer, C.E., Esser, L., Voelcker, N.H. (2022). Theranostic nanoparticles for the management of thrombosis. Theranostics, 12(6), 2773-2800. https://doi.org/10.7150/thno.70001.

ACS
Russell, P.; Hagemeyer, C.E.; Esser, L.; Voelcker, N.H. Theranostic nanoparticles for the management of thrombosis. Theranostics 2022, 12 (6), 2773-2800. DOI: 10.7150/thno.70001.

NLM
Russell P, Hagemeyer CE, Esser L, Voelcker NH. Theranostic nanoparticles for the management of thrombosis. Theranostics 2022; 12(6):2773-2800. doi:10.7150/thno.70001. https://www.thno.org/v12p2773.htm

CSE
Russell P, Hagemeyer CE, Esser L, Voelcker NH. 2022. Theranostic nanoparticles for the management of thrombosis. Theranostics. 12(6):2773-2800.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use